1. Mahlich J, Kamae I, Rossi B (2017) A New Health Technology Assessment System for Japan? Simulating the potential impact on the price of Simeprevir. Int J Technol Assess Health Care 33(1):121–127
2. Kamae I, Kobayashi M (2010) Value-based pricing of new drugs in japan using the principle of incremental cost-effectiveness ratio. ISPOR Connect 16(4):9–10
3. Kamae I, Murata T, Suman D, Yamabe K, Sugimoto T, Kobayashi M (2013) The survey of the japan-style premium scheme in pharmaceutical pricing decisions. ISPOR 16th annual European congress, Dublin, 5 Nov 2013
4. Central Social Insurance Medical Council Special Committee on Cost-Effectiveness. Pilot implementation of cost-effectiveness evaluation, cost-1, 16 Dec 2015 (in Japanese).
http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000107178.pdf
. Accessed 21 Jul 2017
5. Kamae I (2017) New system on health technology assessment in Japanese Ministry of Health, Labour and Welfare: (1) pilot introduction of ‘cost-effectiveness’ evaluation. Pharm Med Device Regulat Sci 48(2):82–88. (in Japanese)